DIMERIX LIMITED (DXB)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
DXB - DIMERIX LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.48
24 Feb |
0.000 OPEN $0.48 |
0.000 HIGH $0.48 |
0 LOW $0.48 |
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.8 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.4 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 3.3 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -7.2 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -4,190.55 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -141.42 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -141.01 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -68.53 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -141.42 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -166.81 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -7.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 22 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 15.43 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 3.88 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | - |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 26 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 21 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
DXB STOCK CHART
FNArena News on DXB
| 1 |
Australian Broker Call *Extra* Edition – Jan 15, 2025Jan 15 2025 - Daily Market Reports |
| 2 |
Rudi’s View: Banks, WiseTech, Redox & Integral DiagnosticsDec 19 2024 - Rudi's View |
| 3 |
Rudi’s View: Best Buys & Smaller Cap FavouritesDec 12 2024 - Rudi's View |
| 4 |
Australian Broker Call *Extra* Edition – Sep 16, 2024Sep 16 2024 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – Sep 05, 2024Sep 05 2024 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Behring Margin Outlook Still Main Game For CSLFeb 13 2025 - Australia |
| 2 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
| 3 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |
| 4 |
Dr Boreham’s Crucible: Aroa BiosurgeryJul 29 2024 - Small Caps |
| 5 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
| 6 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
| 7 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
| 8 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Radiopharm TheranosticsJul 03 2024 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |